Temple University Gastroparesis Clinical Center

项目摘要 胃轻瘫患者经常患有慢性症状，由于胃轻瘫和胃轻瘫， 缺乏对胃轻瘫的潜在病理生理学的了解，缺乏有效的治疗方法。 天普大学作为临床中心参与NIDDK胃轻瘫临床研究 财团（GpCRC）和坦普尔的拟议研究将有助于实现广泛的，长期的目标， 提高对胃轻瘫患者的认识和治疗水平。PI和坦普尔大学是 有资格继续成为GpCRC的临床中心之一。坦普尔大学拥有广泛的 具有胃轻瘫的临床专业知识，并积极参与研究开发，招募患者参与研究， 手稿出版，并获得辅助研究的资金。圣殿重建的目标是 GpCRC是三重的。首先，在目前的GpCRC研究中继续招募和随访患者：GpR 3， BEST，PBG，PSAG。我们将维持胃轻瘫登记3（GpR 3），以招募400名患者， 患者1 - 4年。GpR 3最近被增强以研究SARS-CoV-2在患者中的作用 胃轻瘫我们继续招募临床试验丁螺环酮早饱和症状 胃轻瘫（BEST）。我们的胃轻瘫（PBG）的病理基础是研究免疫细胞谱， 胃轻瘫我们将从幽门病理生理学开始研究： 患有胃轻瘫症状（PSAGS）。第二，为了更好地了解临床表现， 胃轻瘫患者的症状的病理生理学，我们将开始一个新的登记，胃轻瘫 登记研究4，入组400例新患者。此应用程序包括五个研究领域的建议：1） 评估自身免疫性胃轻瘫; 2）了解进食特征和ARFID样 胃轻瘫患者的症状; 3）评估胃轻瘫可能发生的皮质醇减少症 患者并增加症状严重程度; 4）评估迷走神经和周围神经病变， 胃轻瘫的病理生理共病; 5）进一步增强胃排空造影 (GES)评估胃窦同步性和胃窦幽门十二指肠协调性。第三，开展新的 一项多中心研究，调查胃轻瘫的病理生理学、诊断和治疗。我们的应用程序 提出了一项新的研究，使用GES与DACS的胃病理生理学与治疗结果相关，旨在 了解胃轻瘫的病理生理基础及其与症状的关系。目标是 基于病理生理学和症状的更好的靶向特异性治疗。寺庙的参与和建议 研究将有助于实现NIDDK GpCRC的目标，以促进我们对 胃轻瘫

PROJECT SUMMARY Patients with gastroparesis often suffer with chronic symptoms that are not adequately treated due to both a lack of understanding of the underlying pathophysiology of gastroparesis and lack of effective treatments. Participation of Temple University as a clinical center in the NIDDK Gastroparesis Clinical Research Consortium (GpCRC) and Temple's proposed studies will help achieve the broad, long term objectives of improving the understanding and treatment of patients with gastroparesis. The PI and Temple University are well qualified to continue to be one of the clinical centers in the GpCRC. Temple University has extensive clinical expertise in gastroparesis and has been active in study development, enrolling patients into studies, manuscript publication, and obtaining funding for ancillary studies. The aims for Temple's renewal for the GpCRC are threefold. First, to continue enrollment and follow-up of patients in current GpCRC studies: GpR3, BESST, PBG, PSAG. We will maintain the Gastroparesis Registry 3 (GpR3) to enroll 400 patients with follow- up on patients for 1 to 4 years. GpR3 was recently enhanced to study the effects of SARS-CoV-2 in patients with gastroparesis. We continue to enroll in the clinical trial Buspirone for Early Satiety and Symptoms of Gastroparesis (BESST). Our Pathological Basis of Gastroparesis (PBG) is studying immune cell profiles in gastroparesis. We will start our study on pyloric pathophysiology: Pyloric Sphincter Abnormalities in Patients with Gastroparesis Symptoms (PSAGS). Second, to better understand the clinical manifestations and pathophysiology of patients with symptoms of gastroparesis, we will start a new registry, Gastroparesis Registry 4 for enrollment of 400 new patients. This application includes suggestions for five areas of study: 1) evaluating for autoimmune gastroparesis; 2) understanding meal eating characteristics and ARFID-like symptoms in patients with gastroparesis; 3) assess for hypocortisolism which can occur in gastroparesis patients and add to the symptom severity; 4) assessing for vagal and peripheral neuropathy as pathophysiologic comorbidities in gastroparesis; and 5) further enhancement of gastric emptying scintigraphy (GES) assessing antral synchronicity and antropyloroduodenal coordination. Third, to conduct a new multicenter study investigating the pathophysiology, diagnosis, and treatment of gastroparesis. Our application proposes a new study, Relating Gastric Pathophysiology using GES with DACS to Treatment Outcome, aimed at understanding the pathophysiologic basis of gastroparesis and its relationship to symptoms. The goal is to better target specific treatment based on pathophysiology and symptoms. Temple's participation and proposed studies will help achieve the goal of the NIDDK GpCRC to advance our understanding and treatment of gastroparesis.